IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

New U.S. Biosimilars Bill Gets Mixed Reviews

10:26 AM MDT | April 7, 2008 | Deepti Ramesh

A new House bill on biosimilars is drawing mixed reviews from industry. The Generic Pharmaceutical Association (GPhA; Arlington, VA) calls the Pathway for Biologics Act “a step backward” that puts brand company profits before patient needs, but the Biotechnology Industry Organization (BIO; Washington) says the bill is an important step forward toward follow-on biologics. Representatives Anna Eshoo (D., CA) and Joe Barton (R., TX) introduced the bill last month. Eshoo: Pathway to promote innovation. The bill provides 12 years of data exclusivity for...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa